VBIV - VBI Vaccines Non-GAAP EPS of -$0.09 misses by $0.02 revenue of $0.35M misses by $0.35M
- VBI Vaccines press release ( NASDAQ: VBIV ): Q2 Non-GAAP EPS of -$0.09 misses by $0.02 .
- Revenue of $0.35M (+150.0% Y/Y) misses by $0.35M .
- Two new clinical studies in GBM patients expected to start before the end of 2022
- In partnership with the Government of Canada, new clinical study assessing pan-coronavirus vaccine candidate expected to start in Q3 2022
- Initial Phase 2 human proof of concept combination study data from VBI-2601 + siRNA in chronically infected HBV patients expected by year-end 2022
- VBI ended the second quarter of 2022 with $82.4 million in cash compared with $121.7 million in cash as of December 31, 2021.
- Shares -11.21% PM.
For further details see:
VBI Vaccines Non-GAAP EPS of -$0.09 misses by $0.02, revenue of $0.35M misses by $0.35M